RxDoctor Payments Data

Alexander Borowsky, MD

Anatomic Pathology & Clinical Pathology · San Francisco, CANPI 1891777512

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,613 of the $1,783 with a category attached, or 90.4%. E.r. Squibb & Sons, L.L.C. accounts for 90.4% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $1,613, more than ten times the $115 reported in 2019.

$1,783in general payments, 2019–2025

Across 7 payments — averaging $254.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Genentech USA, Inc.$81
  • Roche Molecular Systems, Inc.$42
  • Bristol Myers Squibb$34
  • Roche Diagnostics Corporation$14
$776,506in research payments, 2019–2025

Across 76 payments — averaging $10,217 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ventana Medical Systems, Inc.$764K
  • Pfizer$12K

What the payments were for

  • Consulting fees$1,61390%
  • Food & beverage$17110%

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,783 in reported general payments places this provider in the 80th percentile of 814 anatomic pathology & clinical pathology providers in California.

See all anatomic pathology & clinical pathology providers in California

Medicare billing

Part B allowed, 2024
$28,089
Medicare patients
216
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →